Strides Pharma Science Limited has announced that its Board of Directors will convene on May 18, 2026. The meeting will primarily focus on the approval of the company’s audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Furthermore, the board will deliberate on recommending a final dividend for the same financial period to reward shareholders.
Financial Results and Dividend Review
The company has scheduled a board meeting for Monday, May 18, 2026. During this session, the leadership team will review and approve the financial performance for the final quarter (Q4) and the full fiscal year concluded on March 31, 2026. This comprehensive review will cover both standalone and consolidated financials, providing clarity on the company’s annual growth trajectory.
Shareholder Returns
In addition to the financial performance update, the board is set to consider a final dividend proposal for the 2025-2026 financial year. Investors will be watching closely for the dividend declaration, which serves as a critical indicator of the company’s commitment to returning value to its shareholders.
Trading Window Update
In compliance with internal corporate governance policies, the trading window for designated persons has been closed since April 1, 2026. This period of restricted trading will continue until 48 hours after the official declaration of the financial results to ensure market integrity and transparency regarding non-public price-sensitive information.
Source: BSE
